← Back
$SYRE All transactions

Spyre Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$305K

Shares

6,200

Price

$49

Filed

Apr 3

Insider

Name

Burrows Scott L

Title

Chief Financial Officer

CIK

0001853327

Roles

Officer

Transaction Details

Transaction Date

2026-04-01

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

99,294

Footnotes

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.76 to $50.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. | This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Filing Info

Accession No.

0001853327-26-000003

Form Type

4

Issuer CIK

0001636282

Burrows Scott L's History

Date Ticker Type Value
2026-04-01 SYRE M $109K
2026-04-01 SYRE $305K
2026-04-01 SYRE $65K
2026-04-01 SYRE M $0
2025-09-02 SYRE $300K

Other Insiders at SYRE (90d)

Insider Bought Sold Last
Turtle Cameron
Chief Executive Officer
$740K 2026-04-01
Burrows Scott L
Chief Financial Officer
$65K 2026-04-01
Sloan Sheldon
Chief Medical Officer
$398K 2026-04-01